Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
10 Distinct Kinds of Chinese Neighborhood Specialty Hot Pot - 2Trump says Cuba is 'ready to fall' after capture of Venezuela's Maduro
- 3People Are Sharing The One Picture They Can't See Without Laughing, And It's The Comedy Spiral You Need Today
- 4Benin coup thwarted by loyalist troops, president tells nation
- 5NASA troubleshoots Artemis II toilet problem in otherwise smooth flight
- Vote In favor of Your Favored Menial helper Administration
- 'A completely new manufacturing frontier': Space Forge fires up 1st commercial semiconductor factory in space
- Iranian missile hit on Ne'ot Hovav factory leads to fear of chemical leakage
- Investigating Inside Plan and Home Style: Change Your Residing Space
- Bitcoin momentum builds in Abu Dhabi as global interest surges
- Gunmen open fire near Israeli consulate in Istanbul in possible ISIS-linked attack
- The beauty advent calendar boom is here. Sephora kids are all in.
- Why some African countries are prone to military takeovers
- IDF confirms Iranian missile fragments hit near Kirya, multiple cars ablaze in Ramat Gan
